Nvidia Gains After $20B Groq Licensing Deal for Inference AI

Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals and ImmuCell

  • Stocks rose midday Friday as U.S. markets reopened after the Christmas holiday, with the S&P 500 hitting a fresh high.
  • NVIDIA agreed to a non‑exclusive licensing deal for its inference technology valued at about $20 billion, lifting its shares nearly 2%.
  • Sidus Space, Coupang, Vanda Pharmaceuticals and ImmuCell all saw notable gains after company‑specific news.

U.S. equities traded higher midday Friday as investors returned after the Christmas holiday and the S&P 500 notched a new all‑time high. Markets showed modest ETF gains: the SPDR S&P 500 ETF (SPY) rose 0.08%, the Invesco QQQ Trust (QQQ) gained 0.16%, and the SPDR Dow Jones Industrial Average ETF Trust (DIA) climbed 0.01%.

- Advertisement -

Nvidia Corp. shares rose nearly 2% after the company entered a non‑exclusive licensing agreement with Groq for its inference technology, a deal valued at about $20 billion. Inference technology is software and models that run trained artificial‑intelligence systems to produce outputs from input data.

Sidus Space Inc. jumped more than 22% midday after the firm was awarded a contract under the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program. SIDU stock has climbed about 237% over the past five trading sessions.

According to Reuters, Coupang Inc. rose over 9% after the company said that “all leaked customer information has been deleted”; Coupang stated the suspect was a former employee. CPNG is up roughly 10% over the past five trading sessions.

Vanda Pharmaceuticals Inc. gained nearly 8% in premarket trading before settling about 3% higher as investors awaited an upcoming U.S. Food and Drug Administration decision on Tradipitant, a motion‑sickness prevention drug. VNDA is up 7% over five sessions.

- Advertisement -

ImmuCell Corp. rose nearly 10% midday after announcing a 50% expansion of its First Defense field sales force and plans to scale up drug manufacturing; the company also said it is pausing its Re‑Tain treatment for cows after receiving an “Incomplete Letter” from the FDA. ICCC is up about 2% over the past five trading sessions.

✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.

Previous Articles:

- Advertisement -

Latest News

CZ: Crypto Privacy Key for Business Adoption

Binance co-founder Changpeng "CZ" Zhao identifies a lack of transaction privacy as a major...

Michael Saylor Signals Strategy’s 12th Week of Buying Bitcoin

Strategy has signaled its intent to buy more Bitcoin, continuing a 12-week acquisition streak...

Shiba Inu Down 92%: Can It Still Make Millionaires Today?

Shiba Inu (SHIB) is down approximately 92% from its 2021 all-time high, according to...

Bitcoin Advances Post-Quantum Security With BIP 360

Developers have merged BIP 360 into Bitcoin's GitHub repository as a formal step toward...

Russia Pushes Digital Ruble in BRICS to Ditch Dollar

Russia aims to use its upcoming digital ruble to challenge the dominance of the...

Must Read

How to Set Up a Simple Bitcoin Tip Jar for Your Site or Stream

QUICK LINKSWhat a tip jar is, in plain wordsWhat you needBuild a payment link that just worksAdd a QR code that actually scansWhere to...
🔥 #AD Get 20% OFF any new 12 month hosting plan from Hostinger. Click here!